Elisa R Rea, PA
Physician Assistant · Elk Grove
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 15 years
- Graduated 2011
Offices
2 locations · Regents of the University of California · 562 clinicians in this group
Hospitals listed: University of California Davis Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Elisa R Rea’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- University of California Davis Medical CenterSacramento, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UC Davis Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 1.94 (1.18 to 2.71) · 3,010 cases, Jul 2022 – Jun 2024Worse than the national rate — MRSA Bacteremia: 1.564, Oct 2024 – Sep 2025Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.7 (5.6 to 8) · 1,134 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.6 (10.9 to 14.5) · 1,134 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 127.46 (95.81 to 159.1) · 281 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.18 (0 to 0.57) · 12,625 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.677, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.713, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,436 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for University of California Davis Medical Center
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 1 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.94 (1.18 to 2.71) · 3,010 cases | Worse | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 1.564 | Worse | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.6 to 8) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (10.9 to 14.5) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 127.46 (95.81 to 159.1) · 281 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.57) · 12,625 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.677 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.713 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,436 cases | Better | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.78 to 1.19) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.2 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 662 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 406 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 4,328 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,828 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.13 to 0.46) · 14,152 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.29 (2.92 to 5.66) · 4,920 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.78 (0.46 to 3.09) · 2,250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (1.06 to 3.09) · 4,696 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.46 (5.18 to 13.75) · 2,102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.35 (3.74 to 8.96) · 2,191 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.48 (1.19 to 3.77) · 1,169 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.826 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.669 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 131 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 751 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -25.8 · 127 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.1 · 758 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.6 · 477 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.3 · 203 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.4 to 14.9) · 2,643 cases | No different | Jan 2022 – Dec 2024 |
What patients said (2,768 patients answered, 18% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$36,214
Medicare paid this office $36,214 for 356 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 239 | $16,043 | $51 |
| Short return visit (20+ min) | 105 | $5,127 | $44 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 15 | $4,381 | $292 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 203 | $2,656 | $11 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 28 | $1,630 | $58 |
See all 10 services
| Return visit (30+ min) | 239 | $16,043 | $51 |
| Short return visit (20+ min) | 105 | $5,127 | $44 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 15 | $4,381 | $292 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 203 | $2,656 | $11 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 28 | $1,630 | $58 |
| Influenza vaccine split virus, preservative free | 19 | $1,555 | $82 |
| Administration of influenza virus vaccine | 21 | $717 | $34 |
| Administration of pneumococcal vaccine | 15 | $512 | $34 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 17 | $89 | $5 |
| Automated urinalysis test | 21 | $51 | $2 |
Procedures Medicare counted
| Removal of skin lesions | 1-10 | None |
Who their Medicare patients are
356 Original Medicare patients in 2024. Average age 74 · Under 65 11% · 85 and older 12% · Women 63% · Also on Medicaid 21% · Health risk score 1.32. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 74% · Diabetes 40% · Coronary heart disease 24% · Chronic kidney disease 24% · Heart failure 21% · Depression 19% · COPD 13% · Atrial fibrillation 13% · Cancer 12% · Dementia 8% · Stroke 7%.
The office billed $270,862, Medicare allowed $52,023 and paid $36,214; for 911 services of 37 kinds; $6,043 of it was for drugs given in the office and $30,171 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 356 | 911 | 74 | 1.32 | $270,862 | $36,214 |
| 2023 | 117 | 300 | 70 | 1.09 | $98,249 | $16,361 |
| 2022 | 18 | 40 | 71 | 1.44 | $13,423 | $2,311 |
| 2018 | 53 | 80 | 75 | 1.19 | $10,258 | $4,885 |
| 2017 | 62 | 172 | 73 | 0.89 | $19,210 | $11,601 |
| 2016 | 88 | 222 | 75 | 1.31 | $26,749 | $16,178 |
| 2015 | 24 | 48 | 73 | 1.09 | $5,478 | $3,433 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 68 | $7,622 | $69 |
| New patient visit (45+ min) | 39 | $3,513 | $90 |
| Short return visit (20+ min) | 24 | $1,296 | $46 |
| Insertion of needle into vein for collection of blood sample | 17 | $235 | $8 |
| Automated urinalysis test | 11 | $26 | $2 |
2018: 1 service
| Return visit (30+ min) | 39 | $3,435 | $65 |
2017: 5 services
| Return visit (30+ min) | 32 | $3,297 | $75 |
| Long return visit (40+ min) | 25 | $2,787 | $100 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 18 | $2,014 | $112 |
| Administration of influenza virus vaccine | 22 | $647 | $29 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) | 11 | $180 | $16 |
2016: 7 services
| Return visit (30+ min) | 54 | $6,163 | $77 |
| Long return visit (40+ min) | 30 | $3,129 | $101 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 18 | $2,009 | $112 |
| Short return visit (20+ min) | 19 | $990 | $45 |
| Administration of influenza virus vaccine | 15 | $441 | $29 |
| Administration of pneumococcal vaccine | 11 | $327 | $30 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) | 13 | $187 | $14 |
2015: 1 service
| Return visit (30+ min) | 13 | $1,119 | $80 |
Drugs they prescribed that Part D paid
$242,917
Pharmacies billed $242,917 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (87 of 1,172) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.
977 generic and fewer than 11 brand-name prescriptions · $242,917 in drug cost · 72 antibiotic prescriptions to 56 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 18 | $30,231 | $1,679 |
| Jardiance | 20 | $22,826 | $1,141 |
| Mounjaro | 11 | $19,173 | $1,743 |
| Trulicity | 12 | $13,161 | $1,097 |
| Albuterol Sulfate Hfa | 40 | $1,264 | $32 |
See all 27 drugs
| Ozempic | 18 | $30,231 | $1,679 |
| Jardiance | 20 | $22,826 | $1,141 |
| Mounjaro | 11 | $19,173 | $1,743 |
| Trulicity | 12 | $13,161 | $1,097 |
| Albuterol Sulfate Hfa | 40 | $1,264 | $32 |
| Hydrocodone-Acetaminophen | 36 | $922 | $26 |
| Atorvastatin | 45 | $482 | $11 |
| Gabapentin | 19 | $346 | $18 |
| Fluticasone Propionate | 29 | $311 | $11 |
| Amlodipine Besylate | 32 | $306 | $10 |
| Famotidine | 14 | $302 | $22 |
| Spironolactone | 14 | $292 | $21 |
| Rosuvastatin | 17 | $291 | $17 |
| Allopurinol | 18 | $276 | $15 |
| Losartan | 25 | $233 | $9 |
| Omeprazole | 12 | $221 | $18 |
| Trazodone | 20 | $207 | $10 |
| Metoprolol | 15 | $175 | $12 |
| Levothyroxine | 16 | $160 | $10 |
| Lisinopril | 20 | $142 | $7 |
| Amoxicillin-Clavulanate Potass | 17 | $124 | $7 |
| Doxycycline Hyclate | 12 | $112 | $9 |
| Hydrochlorothiazide | 11 | $94 | $9 |
| Tizanidine | 13 | $84 | $6 |
| Naproxen | 11 | $72 | $7 |
| Lorazepam | 12 | $50 | $4 |
| Zolpidem | 11 | $31 | $3 |
Year by year
| 2024 | 1,172 | 442 | 7% (87) | None | $242,917 |
| 2023 | 500 | 137 | None | None | $61,790 |
| 2022 | 636 | 157 | 2% (13) | None | $24,472 |
| 2021 | 659 | 128 | 3% (18) | None | $40,823 |
| 2020 | 335 | 91 | None | None | $18,673 |
| 2019 | 382 | 107 | None | None | $16,293 |
| 2018 | 382 | 101 | None | 18% | $16,126 |
| 2017 | 283 | 70 | None | 15% | $8,305 |
| 2016 | 411 | 92 | None | None | $16,424 |
| 2015 | 495 | 138 | 4% (21) | None | $23,193 |
| 2014 | 276 | 88 | 5% (15) | None | $7,022 |
| 2013 | 55 | 18 | None | None | $2,353 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Fluoxetine | 12 | $760 | $63 |
| Valsartan | 16 | $410 | $26 |
| Albuterol Sulfate Hfa | 14 | $407 | $29 |
| Zonisamide | 12 | $398 | $33 |
| Buspirone | 14 | $339 | $24 |
| Omeprazole | 12 | $338 | $28 |
| Atorvastatin | 25 | $248 | $10 |
| Amlodipine Besylate | 16 | $151 | $9 |
| Losartan | 15 | $133 | $9 |
2022: 13 drugs
| Levothyroxine | 60 | $927 | $15 |
| Atorvastatin | 45 | $501 | $11 |
| Omeprazole | 16 | $394 | $25 |
| Lisinopril | 28 | $245 | $9 |
| Amlodipine Besylate | 24 | $245 | $10 |
| Alendronate | 11 | $217 | $20 |
| Losartan | 22 | $201 | $9 |
| Escitalopram | 15 | $186 | $12 |
| Hydrochlorothiazide | 21 | $142 | $7 |
| Hydroxyzine | 12 | $110 | $9 |
| Pantoprazole | 14 | $105 | $7 |
| Meloxicam | 13 | $68 | $5 |
| Sertraline | 11 | $60 | $5 |
2021: 14 drugs
| Levothyroxine | 58 | $1,340 | $23 |
| Gabapentin | 14 | $1,147 | $82 |
| Atorvastatin | 44 | $504 | $11 |
| Losartan | 29 | $364 | $13 |
| Nitrofurantoin Mono-Macro | 11 | $310 | $28 |
| Pravastatin | 12 | $282 | $24 |
| Amlodipine Besylate | 20 | $276 | $14 |
| Escitalopram | 15 | $210 | $14 |
| Alendronate | 14 | $191 | $14 |
| Carvedilol | 15 | $118 | $8 |
| Tramadol | 12 | $114 | $10 |
| Lisinopril | 18 | $108 | $6 |
| Trazodone | 11 | $90 | $8 |
| Hydrochlorothiazide | 19 | $35 | $2 |
2020: 6 drugs
| Synthroid | 13 | $665 | $51 |
| Atorvastatin | 39 | $516 | $13 |
| Levothyroxine | 14 | $383 | $27 |
| Lisinopril | 21 | $119 | $6 |
| Donepezil | 13 | $96 | $7 |
| Atenolol | 11 | $96 | $9 |
2019: 8 drugs
| Levothyroxine | 22 | $472 | $21 |
| Atorvastatin | 25 | $416 | $17 |
| Trazodone | 13 | $125 | $10 |
| Alendronate | 11 | $123 | $11 |
| Lisinopril | 16 | $112 | $7 |
| Losartan | 11 | $109 | $10 |
| Azithromycin | 11 | $96 | $9 |
| Hydrochlorothiazide | 22 | $65 | $3 |
2018: 9 drugs
| Levothyroxine | 39 | $822 | $21 |
| Atorvastatin | 32 | $608 | $19 |
| Metoprolol | 11 | $362 | $33 |
| Hydrochlorothiazide | 26 | $131 | $5 |
| Alendronate | 18 | $109 | $6 |
| Losartan | 11 | $96 | $9 |
| Furosemide | 12 | $59 | $5 |
| Trazodone | 13 | $48 | $4 |
| Lisinopril-Hydrochlorothiazide | 11 | $17 | $2 |
2017: 6 drugs
| Levothyroxine | 32 | $538 | $17 |
| Atorvastatin | 30 | $421 | $14 |
| Metoprolol | 18 | $370 | $21 |
| Spironolactone | 14 | $260 | $19 |
| Hydrochlorothiazide | 16 | $120 | $7 |
| Losartan | 12 | $114 | $9 |
2016: 10 drugs
| Levothyroxine | 40 | $690 | $17 |
| Atorvastatin | 36 | $496 | $14 |
| Spironolactone | 11 | $176 | $16 |
| Hydrochlorothiazide | 13 | $110 | $8 |
| Losartan | 14 | $89 | $6 |
| Simvastatin | 21 | $85 | $4 |
| Pantoprazole | 11 | $85 | $8 |
| Metformin | 14 | $82 | $6 |
| Atenolol | 19 | $63 | $3 |
| Lisinopril | 11 | $63 | $6 |
2015: 10 drugs
| Atorvastatin | 45 | $573 | $13 |
| Pioglitazone | 11 | $313 | $28 |
| Levothyroxine | 18 | $279 | $16 |
| Hydrocodone-Acetaminophen | 11 | $151 | $14 |
| Metformin | 12 | $117 | $10 |
| Losartan | 16 | $107 | $7 |
| Atenolol | 19 | $84 | $4 |
| Simvastatin | 21 | $82 | $4 |
| Lovastatin | 13 | $76 | $6 |
| Meloxicam | 12 | $37 | $3 |
2014: 5 drugs
| Atorvastatin | 13 | $287 | $22 |
| Lovastatin | 27 | $151 | $6 |
| Levothyroxine | 11 | $123 | $11 |
| Metoprolol | 21 | $114 | $5 |
| Losartan | 11 | $89 | $8 |
Professional record
- NPI
- 1467727651
- Licence
- CA PA22083
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 20700 Lake Chabot Rd, Ste 107, Castro Valley, CA, 94546
- NPI first listed
- 2012-03-20
- NPI last updated
- 2018-01-03
This is when the NPI record was last certified, not a medical board exam.